Drug profile · INN
ropeginterferon alfa-2b-njft
BESREMI
- US status
- approved
- Patents linked
- 0
- News articles
- 0
Quick answer
ropeginterferon alfa-2b-njft (BESREMI) is an FDA-listed pharmaceutical active ingredient. Associated with Essential Pharma Limited. Route of administration: subcutaneous. Current US regulatory status: approved.
Key facts
Frequently asked questions
What is ropeginterferon alfa-2b-njft?
ropeginterferon alfa-2b-njft (BESREMI) is an FDA-listed pharmaceutical active ingredient. Associated with Essential Pharma Limited. Route of administration: subcutaneous. Current US regulatory status: approved.
What is the brand name for ropeginterferon alfa-2b-njft?
BESREMI is a marketed brand name for ropeginterferon alfa-2b-njft. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ropeginterferon alfa-2b-njft?
ropeginterferon alfa-2b-njft has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.